This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esrig, D. Articles by Cote, R. J. Search for Related Content PubMed PubMed Citation Articles by Esrig, D. Articles by Cote, R. J.

American Journal of Pathology, Vol 143, 1389-1397, Copyright © 1993 by American Society for Investigative Pathology

REGULAR ARTICLES

p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer

D Esrig, CH Spruck 3d, PW Nichols, B Chaiwun, K Steven, S Groshen, SC Chen, DG Skinner, PA Jones and RJ Cote
Urologic Cancer Research Laboratory, University of Southern California, Los Angeles 90033.

Seventy-three transitional cell carcinomas of the bladder were analyzed by immunohistochemistry for p53 nuclear accumulation, and the results were compared to mutations detected in the p53 gene by single strand conformational polymorphism analysis (SSCP) and DNA sequence analysis. Immunohistochemical studies were performed on formalin-fixed, paraffin- embedded tissue sections. A highly significant association between the presence of p53 mutations and p53 nuclear reactivity as detected by immunohistochemistry was found (P = 0.0001). Of 32 tumors that demonstrated p53 mutations by SSCP, 27 (84%) showed p53 nuclear reactivity. Of the five cases that did not demonstrate p53 nuclear reactivity, four had mutations in exon 5. However, of 41 tumors with no evidence of p53 mutation by molecular analysis, 12 (29%) showed p53 immunoreactivity. This indicates that immunohistochemical methods may be more sensitive than SSCP in detecting p53 mutations or that discordant cases represent tumors with accumulation of wild type p53 protein, without mutations at the p53 locus. Of the 15 tumors that were found to have mutations at exon 8, 13 demonstrated high-intensity homogeneous p53 nuclear reactivity by immunohistochemistry, and all mutations located at codon 280 demonstrated high-intensity homogeneous immunoreactivity. However, three of three tumors with exon 6 mutations demonstrated low-level p53 immunoreactivity, and four of six tumors with mutations in exon 5 showed no detectable p53 nuclear reactivity. This indicates that the heterogeneity of immunoreactivity observed when analyzing p53 nuclear accumulation may be related to the site of the p53 gene mutation. Information on tumor grade, stage, lymph node status, disease-free interval, and overall survival were available in 54 patients who had undergone cystectomy. A significant association was observed between p53 alterations (detected by immunohistochemistry and SSCP) and histological tumor grade (P = 0.003) and stage (P = 0.01). We conclude that the immunohistochemical detection of p53 nuclear accumulation in formalin-fixed, paraffin-embedded tissue is highly associated with mutations in the p53 gene; this association has now been demonstrated in a large number of tumors. The heterogeneity of p53 nuclear reactivity seems to be related to the site of mutation in the p53 gene. A small proportion of tumors with a p53 gene mutation do not demonstrate immunohistochemically detectable p53 nuclear accumulation. Furthermore, a small but substantial proportion of tumors demonstrate p53 nuclear reactivity but do not show detectable mutations in the p53 gene by SSCP. Finally, both grade and stage of bladder cancer are related to p53 alterations, detected by immunohistochemistry or molecular methods.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				D. Das, K. Wojno, and M. J. Imperiale BK Virus as a Cofactor in the Etiology of Prostate Cancer in Its Early Stages J. Virol., March 15, 2008; 82(6): 2705 - 2714. [Abstract] [Full Text] [PDF]

				B. George, R. H. Datar, L. Wu, J. Cai, N. Patten, S. J. Beil, S. Groshen, J. Stein, D. Skinner, P. A. Jones, et al. p53 Gene and Protein Status: The Role of p53 Alterations in Predicting Outcome in Patients With Bladder Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5352 - 5358. [Abstract] [Full Text] [PDF]

				Z. Chen, J. Yang, G. Wang, B. Song, J. Li, and Z. Xu Attenuated Expression of Xeroderma Pigmentosum Group C Is Associated with Critical Events in Human Bladder Cancer Carcinogenesis and Progression Cancer Res., May 15, 2007; 67(10): 4578 - 4585. [Abstract] [Full Text] [PDF]

				Y. Matsui, S. Ueda, J. Watanabe, I. Kuwabara, O. Ogawa, and H. Nishiyama Sensitizing Effect of Galectin-7 in Urothelial Cancer to Cisplatin through the Accumulation of Intracellular Reactive Oxygen Species Cancer Res., February 1, 2007; 67(3): 1212 - 1220. [Abstract] [Full Text] [PDF]

				A. P. Mitra, R. H. Datar, and R. J. Cote Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification J. Clin. Oncol., December 10, 2006; 24(35): 5552 - 5564. [Abstract] [Full Text] [PDF]

				F. Maluf, C Cordon-Cardo, D. Verbel, J. Satagopan, M. Boyle, H Herr, and D. Bajorin Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment Ann. Onc., November 1, 2006; 17(11): 1677 - 1686. [Abstract] [Full Text] [PDF]

				E. Lopez-Knowles, S. Hernandez, M. Kogevinas, J. Lloreta, A. Amoros, A. Tardon, A. Carrato, S. Kishore, C. Serra, N. Malats, et al. The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors. Clin. Cancer Res., October 15, 2006; 12(20): 6029 - 6036. [Abstract] [Full Text] [PDF]

				C Mian, M Lodde, E Comploj, L Lusuardi, S Palermo, M Mian, K Maier, and A Pycha Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J. Clin. Pathol., September 1, 2006; 59(9): 984 - 987. [Abstract] [Full Text] [PDF]

				M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]

				M. Ito, H. Nishiyama, J. Watanabe, H. Kawanishi, T. Takahashi, T. Kamoto, T. Habuchi, and O. Ogawa Association of the PIG3 Promoter Polymorphism with Invasive Bladder Cancer in a Japanese Population Jpn. J. Clin. Oncol., February 1, 2006; 36(2): 116 - 120. [Abstract] [Full Text] [PDF]

				A Quintero, J Alvarez-Kindelan, R J Luque, R Gonzalez-Campora, M J Requena, R Montironi, and A Lopez-Beltran Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder J. Clin. Pathol., January 1, 2006; 59(1): 83 - 88. [Abstract] [Full Text] [PDF]

				T. D. Jones, M. Wang, J. N. Eble, G. T. MacLennan, A. Lopez-Beltran, S. Zhang, A. Cocco, and L. Cheng Molecular Evidence Supporting Field Effect in Urothelial Carcinogenesis Clin. Cancer Res., September 15, 2005; 11(18): 6512 - 6519. [Abstract] [Full Text] [PDF]

				A.-F. Dekairelle, B. Tombal, J.-P. Cosyns, and J.-L. Gala Assessment of the Transcriptional Activity of p53 Improves the Prediction of Recurrence in Superficial Transitional Cell Carcinoma of the Bladder Clin. Cancer Res., July 1, 2005; 11(13): 4724 - 4732. [Abstract] [Full Text] [PDF]

				P. J. Goebell, S. Groshen, B. J. Schmitz-Drager, R. Sylvester, M. Kogevinas, N. Malats, G. Sauter, H. B. Grossman, C. P.N. Dinney, F. Waldman, et al. Concepts for Banking Tissue in Urologic Oncology--The International Bladder Cancer Bank Clin. Cancer Res., January 15, 2005; 11(2): 413 - 415. [Full Text] [PDF]

				M Derenzini, C Ceccarelli, D Santini, M Taffurelli, and D Trere The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status J. Clin. Pathol., July 1, 2004; 57(7): 755 - 761. [Abstract] [Full Text] [PDF]

				C. Cordon-Cardo p53 and RB: Simple Interesting Correlates or Tumor Markers of Critical Predictive Nature? J. Clin. Oncol., March 15, 2004; 22(6): 975 - 977. [Full Text] [PDF]

				S. F. Shariat, H. Tokunaga, J. Zhou, J. Kim, G. E. Ayala, W. F. Benedict, and S. P. Lerner p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer J. Clin. Oncol., March 15, 2004; 22(6): 1014 - 1024. [Abstract] [Full Text] [PDF]

				P. Loukopoulos, J. R. Thornton, and W. F. Robinson Clinical and Pathologic Relevance of p53 Index in Canine Osseous Tumors Vet. Pathol., May 1, 2003; 40(3): 237 - 248. [Abstract] [Full Text] [PDF]

				M. Migaldi, A. Sgambato, L. Garagnani, R. Ardito, P. Ferrari, Carmela De Gaetani, A. Cittadini, and G. P. Trentini Loss of p21Waf1 Expression Is a Strong Predictor of Reduced Survival in Primary Superficial Bladder Cancers Clin. Cancer Res., August 1, 2000; 6(8): 3131 - 3138. [Abstract] [Full Text]

				C.-A. O. Nathan, K. Sanders, F. W. Abreo, R. Nassar, and J. Glass Correlation of p53 and the Proto-Oncogene eIF4E in Larynx Cancers: Prognostic Implications Cancer Res., July 1, 2000; 60(13): 3599 - 3604. [Abstract] [Full Text]

				F. Wilkin, N. Gagné, J. Paquette, L. L. Oligny, and C. Deal Pediatric Adrenocortical Tumors: Molecular Events Leading to Insulin-Like Growth Factor II Gene Overexpression J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2048 - 2056. [Abstract] [Full Text]

				M. Burchardt, T. Burchardt, A. Shabsigh, A. De La Taille, M. C. Benson, and I. Sawczuk Current Concepts in Biomarker Technology for Bladder Cancers Clin. Chem., May 1, 2000; 46(5): 595 - 605. [Abstract] [Full Text] [PDF]

				L. M. McShane, R. Aamodt, C. Cordon-Cardo, R. Cote, D. Faraggi, Y. Fradet, H. B. Grossman, A. Peng, S. E. Taube, F. M. Waldman, et al. Reproducibility of p53 Immunohistochemistry in Bladder Tumors Clin. Cancer Res., May 1, 2000; 6(5): 1854 - 1864. [Abstract] [Full Text]

				H. LaRue, P. Allard, M. Simoneau, C. Normand, C. Pfister, L. Moore, F. Meyer, B. Tetu, and Y. Fradet P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers Carcinogenesis, January 1, 2000; 21(1): 101 - 106. [Abstract] [Full Text] [PDF]

				C. Pfister, L. Moore, P. Allard, H. Larue, L. Lacombe, B. Tetu, F. Meyer, and Y. Fradet Predictive Value of Cell Cycle Markers p53, MDM2, p21, and Ki-67 in Superficial Bladder Tumor Recurrence Clin. Cancer Res., December 1, 1999; 5(12): 4079 - 4084. [Abstract] [Full Text] [PDF]

				K. N. Qureshi, T. R. L. Griffiths, M. C. Robinson, C. Marsh, J. T. Roberts, R. R. Hall, J. Lunec, and D. E. Neal TP53 Accumulation Predicts Improved Survival in Patients Resistant to Systemic Cisplatin-based Chemotherapy forMuscle-invasive Bladder Cancer Clin. Cancer Res., November 1, 1999; 5(11): 3500 - 3507. [Abstract] [Full Text] [PDF]

				C. C. R. Lee, T. Ichihara, S. Yamamoto, H. Wanibuchi, K. Sugimura, S. Wada, T. Kishimoto, and S. Fukushima Reduced expression of the CDK inhibitor p27KIP1 in rat two-stage bladder carcinogenesis and its association with expression profiles of p21WAF1/Cip1 and p53 Carcinogenesis, September 1, 1999; 20(9): 1697 - 1708. [Abstract] [Full Text] [PDF]

				J. Zhao, J. Richter, U. Wagner, B. Roth, P. Schraml, T. Zellweger, D. Ackermann, U. Schmid, H. Moch, M. J. Mihatsch, et al. Chromosomal Imbalances in Noninvasive Papillary Bladder Neoplasms (pTa) Cancer Res., September 1, 1999; 59(18): 4658 - 4661. [Abstract] [Full Text] [PDF]

				A. Sgambato, M. Migaldi, B. Faraglia, L. Garagnani, G. Romano, C. De Gaetani, P. Ferrari, G. Capelli, G. P. Trentini, and A. Cittadini Loss of P27Kip1 Expression Correlates with Tumor Grade and with Reduced Disease-free Survival in Primary Superficial Bladder Cancers Cancer Res., July 1, 1999; 59(13): 3245 - 3250. [Abstract] [Full Text] [PDF]

				T. Naka, Y. Iwamoto, N. Shinohara, H. Chuman, and M. Tsuneyoshi p53 Accumulation in Malignant Bone Tumors: An Immunohistochemical Analysis of 217 Cases International Journal of Surgical Pathology, July 1, 1997; 5(1-2): 1 - 9. [Abstract] [PDF]

				W. W. Li, V. W. Li, D. Tsakayannis, X. Xing, L. L. Wood, R. J. Cote, D. G. Skinner, and P. A. Jones p53 and Bladder Cancer N. Engl. J. Med., April 6, 1995; 332(14): 957 - 958. [Full Text]

				D. Esrig, D. Elmajian, S. Groshen, J. A. Freeman, J. P. Stein, S.-C. Chen, P. W. Nichols, D. G. Skinner, P. A. Jones, and R. J. Cote Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer N. Engl. J. Med., November 10, 1994; 331(19): 1259 - 1264. [Abstract] [Full Text]